MXRA5 Is a Novel Immune-Related Biomarker That Predicts Poor Prognosis in Glioma

Figure 9

The MXRA5 survival curves of glioma and GBM in the CGGA and TCGA cohorts. Kaplan-Meier survival analysis showed that, compared to low expression, high expression of MXRA5 conferred a significantly worse prognosis in glioma and GBM patients.

(a)

(b)

(c)

(d)

(e)

(f)